SNY vs SYRE: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
SNY is the larger of the two ($111.81B market cap): the incumbent the market prices for continued execution (8.58x forward earnings, beta 0.26). SYRE is the smaller challenger ($8.98B), still expected to post a loss next year: more room to run, but more to prove. If you believe the upside is worth bigger swings, SYRE fits (beta 3.23). If you want the steadier ride, SNY fits (beta 0.26).
SNY vs SYRE: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | SNY | SYRE | What it tells you |
|---|---|---|---|
| Market cap | $111.81B | $8.98B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 8.58 | -25.61 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.26 | 3.23 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 65% of range | 82% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.36 | 9.40 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how SNY and SYRE affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. SNY and SYRE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined SNY and SYRE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Sanofi (SNY) do?
Sanofi S.A. is one of the world's largest pharmaceutical companies, based in France and organized around biopharma (specialty care, general medicines) and vaccines. Its single most important product is Dupixent, an immunology drug co-developed with Regeneron that treats conditions like eczema, asthma, and COPD; Dupixent sales moved above the roughly four-billion-euro-per-quarter mark in Q1 2026 and reached about 5.7 billion euros in Q3 2026, up nearly 35% year over year, making it the engine of the company's revenue growth. Sanofi also runs a major vaccines business (including the RSV antibody Beyfortus and the newly acquired hepatitis-B vaccine Heplisav-B) and spun off its consumer-health arm, Opella (Allegra, Icy Hot, Dulcolax), in 2025 to focus purely on innovative medicines and vaccines.
What does Spyre Therapeutics (SYRE) do?
Spyre Therapeutics (Nasdaq: SYRE) is a clinical-stage biotechnology company building extended half-life antibodies and antibody combinations aimed at inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, and more recently the skin disease hidradenitis suppurativa (HS). Its lead programs target the TL1A pathway (SPY002 and SPY072) and complementary mechanisms such as alpha4beta7 (SPY001) and IL-23 (SPY003), engineered for less frequent dosing (potentially quarterly or twice-yearly) than existing biologics like Entyvio. The company has no marketed products and generates no product revenue; its worth is tied to clinical progress and the large addressable IBD market.
SNY vs SYRE: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- SNY drivers: Dupixent as the growth engine; Pipeline and new launches.
- SYRE drivers: TL1A pipeline and the 2027 catalyst cadence; Differentiated long-acting dosing.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The clearest risk is concentration in Dupixent: with one product carrying so much of the growth, its eventual loss of patent exclusivity later this decade is the central overhang, and the pipeline may or may not fully replace it. For SYRE, spyre is pre-revenue and unprofitable, with net losses of about $264 million across the last four reported quarters, including $96.1 million in Q3 2026 as R&D spending roughly doubled to $89.2 million, and analysts expect losses of about $3.04 per share in 2026 and $3.69 in 2027 as trials scale, so the valuation rests entirely on future clinical success.
SNY or SYRE: which should you pick?
If the story you believe is SNY's (Dupixent as the growth engine), SNY is the more direct way to own it; if it is SYRE's (TL1A pipeline and the 2027 catalyst cadence), SYRE is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the SNY and SYRE guides.
SNY vs SYRE: the full fundamentals
SNY. Figures are approximate and tied to data as of November 20, 2026. The gap between a ~23x trailing P/E and a ~8.6x forward P/E reflects one-off charges in reported profit versus analyst estimates based on business earnings, and the yield has eased to ~5.3% as the ADR recovered about 12% in the month after third-quarter results, when Sanofi upgraded its full-year 2026 guidance. Sanofi reports in euros, so the dollar value of SNY and its dividend also depends on the euro-to-dollar exchange rate; fourth-quarter results are scheduled for January 28, 2027.
SYRE. Spyre has no product revenue and posts steady losses funding R&D, so traditional earnings and valuation multiples do not apply. Its roughly $8.9 billion market cap (November 20, 2026) reflects expectations for its TL1A, IBD and newer dermatology pipeline, not current cash flow, and sits about 9x book value. Investors weigh a pro forma cash position near $1.47 billion and runway into the second half of 2029 against clinical milestones, the next large one being SKYLINE combination data in Q3 2027.
Headline figures (approximate, November 2026): SNY shows company type Large-cap, diversified global pharmaceutical company (French, US-listed as an ADR on Nasdaq), market cap ~$112 billion (ADR ~$46.58), revenue (ttm) ~51.0 billion euros; Q3 2026 ~14.4 billion, up ~15.7% year over year, q3 2026 eps (actual vs est.) 1.98 vs ~1.51 (adjusted, Yahoo Finance basis); SYRE shows product revenue (ttm) ~$0 (clinical-stage), net loss (last four quarters) ~-$264M, eps (ttm) ~-$2.49, q3 2026 net loss ~-$96M (EPS -$0.94 vs ~-$0.84 est.).
The bottom line: SNY vs SYRE
SNY and SYRE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined SNY and SYRE exposure against your real portfolio. It is not an investment adviser.
Wondering how SNY or SYRE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Sanofi
Ask Walnut's AI anything about SNY and see how it fits what you own.
FAQ
What is the difference between SNY and SYRE?
+
Sanofi S.A. Spyre Therapeutics (Nasdaq: SYRE) is a clinical-stage biotechnology company building extended half-life antibodies and antibody combinations aimed at inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, and more recently the skin disease hidradenitis suppurativa (HS). They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is SNY or SYRE the better stock?
+
Neither is universally better. SNY is the larger incumbent; SYRE is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, SNY or SYRE?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both SNY and SYRE?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of SNY vs SYRE?
+
SNY: The clearest risk is concentration in Dupixent: with one product carrying so much of the growth, its eventual loss of patent exclusivity later this decade is the central overhang, and the pipeline may or may not fully replace it. Drug development is inherently uncertain, as the December 2025 US complete response letter for tolebrutinib in non-relapsing secondary progressive MS showed, even as the EU approved it. Because SNY is an ADR of a euro-reporting company, currency swings between the euro and dollar affect reported results and the dollar value of the dividend, adding volatility unrelated to the business. Pharma also faces pricing pressure, US drug-pricing policy, patent litigation, and competition from large rivals and biosimilars. Vaccine demand is seasonal and competitive, as Beyfortus experienced in the US market. The share price has reflected these worries: SNY touched a 52-week low of ~$39 in October 2026 and RBC cut its Paris-share target to 75 euros from 80. The third-quarter beat brought a ~12% rebound in the month to November 20, but the ADR is still down about 3% for the year at ~$46.58. Deal risk is new: Bloomberg reported in November 2026 that Sanofi is weighing a takeover of Insmed that could be the largest biotech deal since Pfizer's $43 billion Seagen purchase, and a deal of that size would bring integration risk and could absorb cash otherwise returned to shareholders. Reported net income has been volatile, including a loss in the December 2025 quarter. SYRE: Spyre is pre-revenue and unprofitable, with net losses of about $264 million across the last four reported quarters, including $96.1 million in Q3 2026 as R&D spending roughly doubled to $89.2 million, and analysts expect losses of about $3.04 per share in 2026 and $3.69 in 2027 as trials scale, so the valuation rests entirely on future clinical success. Its programs are mostly early to mid-stage, and Phase 2 results do not guarantee Phase 3 or approval; SPY072's misses in the psoriatic arthritis and axial spondyloarthritis sub-studies of SKYWAY already closed off rheumatic diseases for that antibody. The TL1A space is intensely competitive, with Merck's tulisokibart already reporting registrational ulcerative colitis data and Roche, Sanofi/Teva, and others racing ahead, meaning Spyre may reach market later than established rivals. The stock is highly volatile (beta near 3, a 52-week range of about $23 to $111), and equity raises such as the October 2026 $350 million offering and at-the-market sales dilute holders. Any clinical, regulatory, or safety setback carries outsized downside for a company with no product sales.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell SNY or SYRE; figures are approximate and dated (as of November 2026). Verify current data before investing.